Biodexa Pharmaceuticals (BDRX) Free Cash Flow (2013 - 2022)
Biodexa Pharmaceuticals (BDRX) posted Free Cash Flow of $38706.6 for Q4 2022, down 5.16% sequentially from $40812.0 in Q3 2022, and down 84.81% YoY from $254774.0 in Q4 2021.
Biodexa Pharmaceuticals (BDRX) Free Cash Flow (2013 - 2022) Analysis & Trends
Biodexa Pharmaceuticals has reported Free Cash Flow for 8 years, with the latest figure at $38706.6 in Q4 2022.
- Quarterly Free Cash Flow fell 84.81% year-over-year to $38706.6 in Q4 2022, while the trailing twelve-month figure through Jun 2024 was $38706.6 (down 51.32% YoY) and the FY2025 annual result came in at -$7.4 million, up 53.14% from the prior year.
- Free Cash Flow slipped to $38706.6 in Q4 2022 per BDRX's latest filing, from $40812.0 in the prior quarter.
- Over five years, Free Cash Flow peaked at $254774.0 in Q4 2021 and troughed at -$9.2 million in Q4 2020.
- A 4-year average of -$3.9 million and a median of -$4.1 million in 2021 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2021 and 2022: Free Cash Flow soared 102.76% in 2021, then sank 84.81% in 2022.
- Over 4 years, Free Cash Flow stood at -$5.8 million in 2019, then plunged by 58.29% to -$9.2 million in 2020, then jumped by 102.76% to $254774.0 in 2021, then slumped by 84.81% to $38706.6 in 2022.
- According to Business Quant data, Free Cash Flow over the past three periods registered $38706.6, $40812.0, and $254774.0 for Q4 2022, Q3 2022, and Q4 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Biodexa Pharmaceuticals | 64,325.41 | -11.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 38,706.63 |
| Dec 31, 2022 | 38,706.63 |
| Sep 14, 2022 | 40,811.96 |
| Sep 14, 2022 | 40,811.96 |
| Dec 31, 2021 | 254,774.00 |
| Dec 31, 2021 | 254,774.00 |
| Sep 17, 2021 | -4.06 Mn |
| Sep 17, 2021 | -4.06 Mn |
| Dec 31, 2020 | -9.24 Mn |
| Dec 31, 2020 | -9.24 Mn |
| Sep 10, 2020 | -8.81 Mn |
| Sep 10, 2020 | -8.81 Mn |
| Dec 31, 2019 | -5.84 Mn |
| Dec 31, 2019 | -5.84 Mn |
| Dec 31, 2016 | -14.59 Mn |
| Dec 31, 2016 | -14.59 Mn |
| Dec 31, 2015 | -17.45 Mn |
| Dec 31, 2015 | -17.45 Mn |
| Dec 31, 2014 | -7.01 Mn |
| Dec 31, 2014 | -7.01 Mn |